Login to Your Account

Pharmasset Amends HCV Trials, Sends Ripples Through Space

By Jennifer Boggs
Managing Editor

Monday, December 19, 2011
Investors in hepatitis C virus (HCV) firms went into panic mode Friday after Pharmasset Inc. dropped guanine nucleotide analogue PSI-938 from its Phase IIb QUANTUM trial after routine monitoring unveiled laboratory abnormalities associated with liver function in patients receiving the drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription